CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,247,036 | +65.0% | 479,053 | 0.0% | 3.80% | +118.8% |
| Q2 2023 | $8,632,535 | +49.1% | 479,053 | +32.9% | 1.74% | +15.6% |
| Q1 2023 | $5,787,896 | -14.9% | 360,392 | -3.0% | 1.50% | -14.7% |
| Q4 2022 | $6,800,994 | -5.1% | 371,639 | +1.9% | 1.76% | +4.0% |
| Q3 2022 | $7,163,000 | +4.7% | 364,710 | -0.5% | 1.70% | -10.7% |
| Q2 2022 | $6,839,000 | -15.0% | 366,676 | 0.0% | 1.90% | -12.0% |
| Q1 2022 | $8,049,000 | -25.4% | 366,676 | -3.5% | 2.16% | +9.8% |
| Q4 2021 | $10,790,000 | +71.8% | 379,792 | +27.3% | 1.97% | +102.0% |
| Q3 2021 | $6,281,000 | – | 298,392 | – | 0.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |